Immediate Impact
2 from Science/Nature 56 standout
Citing Papers
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
The interaction of innate immune and adaptive immune system
2024 Standout
Works of Greg Dueck being referenced
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study
2018
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Greg Dueck | 458 | 332 | 219 | 13 | 550 | |
| Heidi Nyman | 492 | 347 | 205 | 22 | 631 | |
| J Pierson | 513 | 339 | 237 | 13 | 645 | |
| B Coiffier | 385 | 231 | 263 | 13 | 511 | |
| Kamal Bouabdallah | 420 | 337 | 227 | 26 | 512 | |
| Abdulwahab J. Al-Tourah | 515 | 357 | 184 | 18 | 602 | |
| Marisol Mateo | 501 | 225 | 366 | 8 | 612 | |
| DA Filippa | 441 | 293 | 271 | 19 | 532 | |
| K. Adams | 323 | 256 | 133 | 8 | 512 | |
| A Kunlin | 395 | 266 | 255 | 18 | 620 | |
| Manuel F. Rosado | 328 | 244 | 96 | 14 | 483 |
All Works
Login with ORCID to disown or claim papers
Loading papers...